Several factors such as tumor morphology and grade, tumor size, lymph node metastases, and expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2/neu) are currently known as important parameters essential for treatment tailoring. This evidence concerns the gene ERBB2 and neoplasm.